Matsui I, Sakata S, Ogawa T, Takuno H, Sarui H, Komaki T, Manshouri T, Atassi M Z
Third Department of Internal Medicine, Gifu University School of Medicine, Japan.
Endocr J. 1993 Oct;40(5):607-12. doi: 10.1507/endocrj.40.607.
Twenty three male Wistar rats were divided into five groups and were immunized with five overlapping synthetic peptides (Group I (n = 5), peptide 12-30; Group II (n = 5), 24-44; Group III (n = 4), 308-328; Group IV (n = 5), 324-344; and Group V (n = 4), 339-364) of human thyrotropin receptor (TSHR), which had been conjugated with rabbit serum albumin. Sera obtained 34 days after the first immunization were investigated for their ability to displace 125I-TSH binding to thyrotropin receptor (thyrotropin binding inhibitor immunoglobulins (TBII)). In addition, biological activity, namely thyroid stimulating (TSAb) or blocking (TSBAb) activities in them were tested with cultured porcine thyroid cells. TBII activities in Group I, II, III, IV, and V rats were 12.6 +/- 4.1% (range 9.2-17.2%), 16.3 +/- 4.0% (range 11.7-22.0%), 16.7 +/- 4.9% (range 13.2-20.1%), 14.5 +/- 5.7% (range 8.1-19.0%), and 13.8 +/- 6.3% (range 8.1-14.3%), respectively, which were not significantly different from control rat sera (12.3 +/- 6.7%, range 1.2-20.1%). TSAb activities in Group I, II, III, IV, and V rats were 608 +/- 675% (range 275-1813%), 234 +/- 26% (range 209-265%), 313 +/- 175% (range 187-568%), 190 +/- 63% (range 145-301%), and 134 +/- 24% (range 107-158%), respectively. TSAb activities in Group I, II, III, and IV rats were significantly higher than those from control rat sera (P < 0.01) while those of Group V were not significantly different from control rat sera. None of the rats in each group exhibited TSBAb activity.(ABSTRACT TRUNCATED AT 250 WORDS)
将23只雄性Wistar大鼠分为五组，用五种与人促甲状腺激素受体（TSHR）重叠的合成肽进行免疫（第一组（n = 5），肽12 - 30；第二组（n = 5），24 - 44；第三组（n = 4），308 - 328；第四组（n = 5），324 - 344；第五组（n = 4），339 - 364），这些肽已与兔血清白蛋白偶联。首次免疫34天后采集的血清，检测其置换125I - TSH与促甲状腺激素受体结合的能力（促甲状腺激素结合抑制性免疫球蛋白（TBII））。此外，用培养的猪甲状腺细胞检测其中的生物活性，即甲状腺刺激（TSAb）或阻断（TSBAb）活性。第一组、第二组、第三组、第四组和第五组大鼠的TBII活性分别为12.6±4.1%（范围9.2 - 17.2%）、16.3±4.0%（范围11.7 - 22.0%）、16.7±4.9%（范围13.2 - 20.1%）、14.5±5.7%（范围8.1 - 19.0%）和13.8±6.3%（范围8.1 - 14.3%），与对照大鼠血清（12.3±6.7%，范围1.2 - 20.1%）无显著差异。第一组、第二组、第三组、第四组和第五组大鼠的TSAb活性分别为608±675%（范围275 - 1813%）、234±26%（范围209 - 265%）、313±175%（范围187 - 568%）、190±63%（范围145 - 301%）和134±24%（范围107 - 158%）。第一组、第二组、第三组和第四组大鼠的TSAb活性显著高于对照大鼠血清（P < 0.01），而第五组与对照大鼠血清无显著差异。每组大鼠均未表现出TSBAb活性。（摘要截断于250字）
